Abstract:
:Clinical studies that have evaluated serotonergic medications to reduce alcohol consumption have yielded conflicting results. These studies primarily treated patients with alcohol dependence, excluding those with a current depressive disorder, in an effort to differentiate any medication effects directly on drinking from those on mood. Yet despite the exclusion of current depression, a group of alcohol-dependent patients who are not depressed can be highly heterogeneous. For example, this subgroup can include those with a lifetime depressive disorder. If these patients were more sensitive to serotonergic medications than patients without a lifetime depressive disorder, medication effects in a subgroup of patients who were not depressed could be obscured. Thus, the purpose of this study was to examine the efficacy of sertraline for treating alcohol dependence in patient groups that were differentiated by the presence or absence of lifetime depression. This study examined the effectiveness of sertraline (200 mg/day) or placebo for 14 weeks in 100 alcohol-dependent subjects with (N = 53) or without (N = 47) a lifetime diagnosis of comorbid depression. Sertraline treatment seemed to provide an advantage in reducing drinking in alcohol-dependent patients without lifetime depression, illustrated best with a measure of drinking frequency during treatment. However, sertraline was no better than placebo in patients with a diagnosis of lifetime comorbid depression, and current depression did not change the results. Treatment with selective serotonin reuptake inhibitors may be useful in alcohol-dependent patients who are not depressed. Subtyping those with alcohol dependence on the basis of the absence versus the presence of a lifetime depressive disorder may help to resolve conflicting findings in the literature on the treatment of alcohol dependence with serotonergic medications.
journal_name
J Clin Psychopharmacoljournal_title
Journal of clinical psychopharmacologyauthors
Pettinati HM,Volpicelli JR,Luck G,Kranzler HR,Rukstalis MR,Cnaan Adoi
10.1097/00004714-200104000-00005subject
Has Abstractpub_date
2001-04-01 00:00:00pages
143-53issue
2eissn
0271-0749issn
1533-712Xjournal_volume
21pub_type
临床试验,杂志文章,随机对照试验abstract::We compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the DSM-IV diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year. Blood samples were obtained after an 11-hour (+/...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/01.jcp.0000227705.56870.06
更新日期:2006-08-01 00:00:00
abstract:PURPOSE:This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. METHODS:Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/JCP.0000000000000674
更新日期:2017-04-01 00:00:00
abstract::The antidepressant mirtazapine is an alternative to classical hypnotics, and this study investigated the efficacy and safety of esmirtazapine (Org 50081, the maleic acid salt of S-mirtazapine) in patients given a diagnosis of primary insomnia after acute (2-day) treatment. Patients aged 18 to 65 years with primary ins...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1097/JCP.0000000000000546
更新日期:2016-10-01 00:00:00
abstract:BACKGROUND:We examined the influence of prior antidepressant treatment trials on the likelihood of depressive relapse, and time to depressive relapse, during maintenance therapy of bipolar II disorder in treatment-responsive subjects who had recovered from a major depressive episode. METHODS:Data were derived from a p...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/JCP.0000000000001049
更新日期:2019-07-01 00:00:00
abstract::The clinician using neuroleptic drugs for the treatment of psychotic patients must face a number of questions regarding whether and how to use anticholinergic drugs when extrapyramidal side effects appear. This article explores some of these questions, suggests how they might best be answered, reviews the studies whic...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1983-10-01 00:00:00
abstract:BACKGROUND:Dopaminergic dysfunction, namely, dopamine transporter (DAT) availability variations in patients with drug-naive schizophrenia after long-term treatment, is still not well understood. The aims of the study were to explore (i) whether the DAT availability in patients with drug-naive schizophrenia differed aft...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000000632
更新日期:2017-02-01 00:00:00
abstract::The sex prevalence of schizophrenia is approximately equal, and yet clinical trials of new therapeutic drugs have been conducted, for the most part, with male participants. The authors reviewed the percentage of women in schizophrenia clinical trials of the new "atypical" antipsychotic medications. MEDLINE and Cochran...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/01.jcp.0000236652.78168.ee
更新日期:2006-10-01 00:00:00
abstract::It has been suggested that maintenance treatment of patients who have remitted panic disorder with agoraphobia beyond the six months of acute phase imipramine treatment may decrease the risk of relapse. This study further explores the relationship between relapse and duration of imipramine treatment in this population...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004714-200206000-00010
更新日期:2002-06-01 00:00:00
abstract::The aim of this study was to compare the disposition of the tricyclic antidepressant clomipramine (C) in Japanese and Swedish patients receiving continuous treatment. Therapeutic drug monitoring data for C and the active metabolite N-desmethylclomipramine (DC) in Japanese patients receiving monotherapy (N = 12) and in...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004714-199910000-00002
更新日期:1999-10-01 00:00:00
abstract::The selective serotonin reuptake inhibitor antidepressant fluoxetine inhibits alprazolam metabolism in vivo by inhibition of the cytochrome P450 3A4 enzyme. Citalopram is a selective serotonin reuptake inhibitor antidepressant that has not yet been fully evaluated with respect to its potential for cytochrome P450 3A4-...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/01.jcp.0000085407.08426.e1
更新日期:2003-08-01 00:00:00
abstract::In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2.25 mg x kg(-1) x day(-1), 59 adhered to the regimen and showed a marked and stable resp...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004714-200010000-00010
更新日期:2000-10-01 00:00:00
abstract:BACKGROUND:Despite initial reports of efficacy in bipolar depression, multicenter trials did not show aripiprazole to be better than placebo, possibly because the doses used were too high, leading to lower efficacy and high dropout rates. This study evaluated the effects of low-dose aripiprazole. Extensive clinical exp...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000000636
更新日期:2017-02-01 00:00:00
abstract::Alcohol cue-induced brain activation has been studied extensively in alcoholics. However, little is known about the impact of standard treatment protocols on this phenomenon. The current study aimed at investigating the impact of the anticraving substance acamprosate on alcohol cue-related brain activity. Patients und...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0b013e318267b586
更新日期:2012-10-01 00:00:00
abstract:CONTEXT:Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder. OBJECTIVE:To evaluate duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, on improvement of emotional and painful phy...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1097/01.jcp.0000132448.65972.d9
更新日期:2004-08-01 00:00:00
abstract::Zolpidem is an imidazopyridine hypnotic that is biochemically distinct from classic benzodiazepine agonists in that it may be selective for the BZ1 receptor subtype and shows a different pattern of distribution of binding sites. The present study compared the learning, recall, performance, subject-rated and observer-r...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004714-199604000-00007
更新日期:1996-04-01 00:00:00
abstract::Prospectively identified fluoxetine-exposed pregnancies were evaluated to determine whether fluoxetine, a serotonin reuptake inhibitor commonly used for the treatment of depression and obsessive-compulsive disorder, might be associated with neonatal complications after maternal fluoxetine exposure during the third tri...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004714-199512000-00005
更新日期:1995-12-01 00:00:00
abstract::Aripiprazole is widely used to treat schizophrenia. Plasma levels of aripiprazole and its active metabolite dehydroaripiprazole and their clinical responses in patients were explored. Forty-five (male/female: 19/26) patients with schizophrenia were treated with aripiprazole after a washout period of at least 3 days. T...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/JCP.0b013e3182356255
更新日期:2011-12-01 00:00:00
abstract:BACKGROUND:Posttraumatic stress disorder (PTSD) is one of the chronic and disabling psychiatric disorders, particularly in combat veterans. In a case series, rivastigmine was suggested to be an effective augmentation in treatment of PTSD. The aim of the present study was to evaluate this finding in a randomized control...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/JCP.0000000000000624
更新日期:2017-02-01 00:00:00
abstract::Lithium alone or in combination with other psychotherapeutic drugs has long been the gold standard of management for bipolar disorder (BD). Recognition of its limitations in the acute and chronic management of BD has led to the development of alternative therapies. One such approach involves the use of antiepileptic d...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004714-200212000-00010
更新日期:2002-12-01 00:00:00
abstract::Therapeutic drug monitoring studies of selective serotonin reuptake inhibitor (SSRI) antidepressants thus far failed to identify a clear concentration-response relationship in major depression. Majority of the previous studies defined clinical response as 50% or greater reduction from baseline in depression rating sca...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0b013e3181730850
更新日期:2008-06-01 00:00:00
abstract::The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000000311
更新日期:2015-06-01 00:00:00
abstract::Newer atypical antipsychotics demonstrate superior effectiveness, with a diminished incidence of extrapyramidal side effects compared with older typical antipsychotics, but they have been associated with the development of obesity and new-onset diabetes. A small number of reports documenting modest hypertriglyceridemi...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004714-200108000-00003
更新日期:2001-08-01 00:00:00
abstract::In a double-blind study of 34 randomly assigned depressed inpatients, antidepressant-induced electroencephalogram (EEG) abnormalities were compared in amitriptyline-treated versus bupropion-treated patients. Drug-free baseline EEGs plus one or more repeat EEGs under pharmacokinetic steady state conditions were obtaine...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1984-10-01 00:00:00
abstract::Lithium is clinically available for the treatment of mood disorders. However, it has remained unclear how lithium acts on the brain to produce its effects. The aim of this study was to evaluate the effects of chronic lithium on human brain activity using positron emission tomography and clarify the correlation between...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/jcp.0b013e31815a23c2
更新日期:2007-12-01 00:00:00
abstract:OBJECTIVE:Researchers, by studying first-generation antipsychotics, have established an early prediction model, which had a favorable specificity but a low sensitivity. This study aims to optimize early prediction of treatment response for schizophrenia using a novel statistic method that can be done even under the Mic...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/01.jcp.0000246211.95905.8c
更新日期:2006-12-01 00:00:00
abstract:BACKGROUND:Antipsychotics (APs) are known to exacerbate symptoms of benign prostate hyperplasia (BPH) and may even cause urinary retention. The anticholinergic effects of APs and their dopamine D2- and α-receptor blockade may lead to voiding dysfunction of BPH patients. The objective of our study was to investigate whe...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000000928
更新日期:2018-10-01 00:00:00
abstract::Twenty-four healthy male and female subjects, who participated in this randomized, double-blind, crossover study, received single nighttime doses of zaleplon 10 mg (therapeutic dose), zaleplon 20 mg, zolpidem 10 mg (therapeutic dose), zolpidem 20 mg, triazolam 0.25 mg (positive control), and placebo. Subjective behavi...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004714-200006000-00007
更新日期:2000-06-01 00:00:00
abstract::A randomized, double-blind, placebo-controlled study was conducted to assess the efficacy of risperidone in the treatment of developmental stuttering in 16 adults. Eight subjects received placebo and eight received risperidone at 0.5 mg once daily at night, increased to a maximum of 2 mg/day. After 6 weeks of treatmen...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004714-200008000-00013
更新日期:2000-08-01 00:00:00
abstract::This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del) and the Ser9Gly DRD3 variants, (c) 2 glutathione S-transferases (GSTT1 and GSTM1), and (d) variations in the PgP gene, ...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/01.jcp.0000177546.34799.af
更新日期:2005-10-01 00:00:00
abstract::Fifty-five patients completed a 5-week double-blind study comparing alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. There was no concomitant behavioral treatment. Patient and therapist rating scales included Sheehan's Panic and Anxiety Attack Scales, the Mark...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1989-02-01 00:00:00